Gale Scott

Major drug companies are starting to make cheap versions of blockbuster hepatitis C drugs available to people in poor and many middle-income nations.

Statins show promise to reduce liver disease incidence in coinfected patients.

Traveling a longer distance to a medical center was not associated with spending more time on a waiting list.

Clean needle programs have reduced HIV incidence among injection drug abusers by 80% from 1990 to 2006.

Anemia caused by chemotherapy for lymphoid malignancies improved in patients with non-Hodgkin's lymphoma and multiple myeloma.

The $750 per pill price of pyrimethamine could soon be undercut by a new compound selling for $1 per pill.

Number of infected people is projected to drop below 1 million by 2020, but with substantial HCV disease and death burden.

Baricitinib improved disease activity in patients not responding to conventional or biologic DMARDs.

Biosimilar may offer patients with RA drug cost relief in the near future.

Experimental DMARD may be clinically beneficial for active rheumatoid arthritis treatment.

Patients with Crohn's disease taking angiotensin converting enzyme inhibitors have significantly higher rate of hospitalizations.

More than half of patients did not return to physicians for follow-up care.

Pan-virals show potential to work across all HCV genotypes.

New guidelines based on overwhelming clinical evidence that ART is effective.

Tourists with prescriptions for medical marijuana will be able to apply for a permit to let them buy it in Jamaica.